You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Significant revenue from molecular and rapid diagnostic testing for SARS-CoV-2 offset declines in core lab volumes.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
Under the original March agreement, Thermo Fisher was going to pay €39 per Qiagen share, a 23 percent premium that the amendment now raises to 35 percent.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The firm's various COVID-19 molecular test offerings offset declines in core laboratory and point-of-care segments.
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Synlab will make a gastrointestinal testing service that is based on Microba's gut microbiome test available to its network of doctors and clinics.
The data collected could improve understanding of drug efficacy, deliver precision cancer care, guide clinical trial matching, and advance research projects.
Precommercial firm Enancio has developed lossless compression technology that Illumina hopes will cut sequencing storage costs by 80 percent for its customers.
KogeneBiotech and Trax Management's tests may be performed by any CLIA-certified high-complexity lab, while the Compass test may only be performed by its developer.
The firm said it expects FDA clearance for its Acuitas AMR Gene Panel, although it has been delayed due to the agency's extended review timelines.
Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on various biomarkers.
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
BTIG put a $20 target price on Genetron's shares, while Canaccord Genuity is targeting $19 per share for the Chinese genomics and cancer diagnostics firm.
The Emeryville, California-based company reported revenues of $13.8 million for the three months ended March 31, up from $12.6 million in the year-ago period.
First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.
The company said it has signed a US distribution agreement for its COVID-19 test with an undisclosed strategic partner.
Vela Diagnostics said that the RT-PCR-based test has also received provisional authorization from the Health Sciences Authority in Singapore.
The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.
According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.
NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.